The findings described here provide a basis for the development of a new generation of PD-1-cis-targeted IL-2Rβγ agonists, preferentially targeting antigen-specific stem-like T cells but expanding an alternative population of better effector cells with enhanced therapeutic potential for the treatment of cancer and chronic infections. Here, PDCD1 is linked to cancer.